Histone deacetylase inhibitors: Anticancer compounds

被引:69
|
作者
Smith, Karen T. [1 ]
Workman, Jerry L. [1 ]
机构
[1] Stowers Inst Med Res, Kansas City, MO 64110 USA
关键词
HDAC; Acetylation; Chromatin; Cancer; Cell cycle; SUBEROYLANILIDE HYDROXAMIC ACID; ESTROGEN-RECEPTOR-ALPHA; CARCINOMA-CELL-LINES; BREAST-CANCER CELLS; PML-RAR-ALPHA; VALPROIC ACID; PROTEASOMAL DEGRADATION; DNA METHYLTRANSFERASE-1; SODIUM-BUTYRATE; HDAC INHIBITORS;
D O I
10.1016/j.biocel.2008.09.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reversible acetylation of proteins is mediated by histone acetytransferases which acetylate proteins and historic deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gone repression. Importantly, acetylation also occurs on non-histone proteins all this call affect the activity and stability of these proteins. Aberrant epigenetic changes ate a common hallmark Of tumors and Imbalances in the activities of deacetylases have been associated with cancers. Accordingly, inhibitors to the historic deacetylases are in clinical trials for the treatment of several cancer types. These drugs mediate a number Of molecular changes and ill turn Call induce cell cycle arrest, apoptosis or differentiation of cancer cells while displaying limited toxicity in normal cells. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 50 条
  • [31] Histone deacetylase inhibitors: A new wave of molecular targeted anticancer agents
    Budillon, Alfredo
    Di Gennaro, Elena
    Bruzzese, Francesca
    Rocco, Monia
    Manzo, Giuseppe
    Caraglia, Michele
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (02) : 119 - 134
  • [32] Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors
    Patel, Hiren
    Chuckowree, Irina
    Coxhead, Peter
    Guille, Matthew
    Wang, Minghua
    Zuckermann, Alexandra
    Williams, Robin S. B.
    Librizzi, Mariangela
    Paranal, Ronald M.
    Bradner, James E.
    Spencer, John
    MEDCHEMCOMM, 2014, 5 (12) : 1829 - 1833
  • [33] Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
    Patel, Preeti
    Wahan, Simranpreet K.
    Vishakha, S.
    Das Kurmi, Balak
    Das Gupta, Ghanshyam
    Rajak, Harish
    Asati, Vivek
    CURRENT CANCER DRUG TARGETS, 2023, 23 (01) : 47 - 70
  • [34] Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
    Mottamal, Madhusoodanan
    Zheng, Shilong
    Huang, Tien L.
    Wang, Guangdi
    MOLECULES, 2015, 20 (03) : 3898 - 3941
  • [35] Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents
    El-Awady, Raafat
    Saleh, Ekram
    Hamoudi, Rifat
    Ramadan, Wafaa S.
    Mazitschek, Ralph
    Nael, Manal A.
    Elokely, Khaled M.
    Abou-Gharbia, Magid
    Childers, Wayne E.
    Srinivasulu, Vunnam
    Aloum, Lujain
    Menon, Varsha
    Al-Tel, Taleb H.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 42
  • [36] Histone deacetylase inhibitors
    Miller, TA
    Witter, DJ
    Belvedere, S
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (24) : 5097 - 5116
  • [37] Histone deacetylase inhibitors
    Grant, S
    ANNALS OF ONCOLOGY, 2005, 16 : 29 - 29
  • [38] Histone Deacetylase Inhibitors
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : S1808 - S1809
  • [39] Histone deacetylase inhibitors
    Sharma, S.
    LUNG CANCER, 2006, 54 : S51 - S51
  • [40] Histone deacetylase inhibitors
    Miller, TA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U162 - U162